OPHTHETIC Drug Patent Profile
✉ Email this page to a colleague
When do Ophthetic patents expire, and when can generic versions of Ophthetic launch?
Ophthetic is a drug marketed by Allergan and is included in one NDA.
The generic ingredient in OPHTHETIC is proparacaine hydrochloride. There is one drug master file entry for this compound. Six suppliers are listed for this compound. Additional details are available on the proparacaine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ophthetic
A generic version of OPHTHETIC was approved as proparacaine hydrochloride by BAUSCH AND LOMB on September 29th, 1995.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for OPHTHETIC?
- What are the global sales for OPHTHETIC?
- What is Average Wholesale Price for OPHTHETIC?
Summary for OPHTHETIC
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 47 |
| Patent Applications: | 4,567 |
| DailyMed Link: | OPHTHETIC at DailyMed |
US Patents and Regulatory Information for OPHTHETIC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergan | OPHTHETIC | proparacaine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 012583-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
